[HTML][HTML] Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study

G Sozzi, M Boeri, M Rossi, C Verri… - Journal of clinical …, 2014 - ncbi.nlm.nih.gov
G Sozzi, M Boeri, M Rossi, C Verri, P Suatoni, F Bravi, L Roz, D Conte, M Grassi…
Journal of clinical oncology, 2014ncbi.nlm.nih.gov
Purpose Recent screening trial results indicate that low-dose computed tomography (LDCT)
reduces lung cancer mortality in high-risk patients. However, high false-positive rates, costs,
and potential harms highlight the need for complementary biomarkers. The diagnostic
performance of a noninvasive plasma microRNA signature classifier (MSC) was
retrospectively evaluated in samples prospectively collected from smokers within the
randomized Multicenter Italian Lung Detection (MILD) trial.
Abstract
Purpose
Recent screening trial results indicate that low-dose computed tomography (LDCT) reduces lung cancer mortality in high-risk patients. However, high false-positive rates, costs, and potential harms highlight the need for complementary biomarkers. The diagnostic performance of a noninvasive plasma microRNA signature classifier (MSC) was retrospectively evaluated in samples prospectively collected from smokers within the randomized Multicenter Italian Lung Detection (MILD) trial.
ncbi.nlm.nih.gov